A clinical trial is a research study designed to treat a specific type of disease. Cancer clinical trials determine if a new method of treatment or diagnosis is effective.
Dana-Farber/Boston Children's Cancer and Blood Disorders Center researchers initiate multiple new pediatric cancer clinical studies each year, investigating new treatments for all forms of childhood cancer. Many of our findings have built the foundation for the newest medications and state-of-the-art procedures we use to treat childhood cancer.
View pediatric clinical trials
Clinical trials are important in the long-term treatment of childhood cancer, and discoveries made years ago through clinical trials are now the standard of care for conditions like leukemia and lymphoma. By participating in a trial, your child will help us develop improved treatments for future children with the same condition.
Participation in clinical trials is completely voluntary. Before your child begins a trial, we will fully explain all parts of the treatment plan and fill out formal consent forms. You may remove your child from the medical study at any time.
Many DF/CHCC investigators assume leadership roles in national cooperative research groups investigating new, or phase I, approaches for treating all forms of childhood cancer. DF/CHCC is the only pediatric program in New England that offers access to many of these phase I studies.
The cooperative research groups that Dana-Farber Cancer Institute and Boston Children's Hospital physicians, (and in some cases, nurses, pharmacists and research coordinators) contribute to include:
The Dana-Farber ALL Consortium brings together eight institutions in the United States and Canada to work together to develop and oversee medical studies for children with Acute Lymphoblastic Leukemia (ALL), with the goal of improving survival while minimizing toxicity.
COG is a collaborative research organization comprised of doctors, nurses, pharmacists and research coordinators dedicated to improving the treatment of childhood cancers. DF/CHCC is one of only 20 institutions nationwide conducting COG phase I clinical trials. On their Curesearch.org website, COG offers information for patients and families regarding cancer diagnosis, treatment, supportive care, and after treatment.
The PBTC is a multidisciplinary cooperative research organization devoted to the study of correlative tumor biology and new therapies for primary CNS tumors of childhood. DF/CHCC was selected as one of the original nine member institutions because of its extensive experience with pediatric brain tumor clinical trials and its depth of the laboratory and imaging capabilities.
NANT is a group of 14 universities and Children’s Hospitals with strong research and treatment programs for neuroblastoma that tests promising new therapies for high-risk and relapsed neuroblastoma. The group is supported and funded by the National Cancer Institute.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free:
(866) 408-DFCI (3324)